Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies

Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies

Abstract Background Long-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebuliz...

Full description

Bibliographic Details
Main Authors: James F. Donohue, Thomas Goodin, Robert Tosiello, Alistair Wheeler
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Respiratory Research
Subjects:
COPD
eFlow® CS
GOLDEN
Glycopyrrolate
LAMA
Nebulizer
Online Access:http://link.springer.com/article/10.1186/s12931-017-0681-z

Internet

http://link.springer.com/article/10.1186/s12931-017-0681-z

Similar Items